Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Department of Ophthalmology, Bergman Clinics, Naarden, the Netherlands.
Ophthalmic Physiol Opt. 2022 Jul;42(4):849-857. doi: 10.1111/opo.12984. Epub 2022 Apr 2.
To determine which demographic and clinical characteristics are predictive of vision-related quality of life (VrQoL) and quality of life (QoL) in patients with macular oedema receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment.
Vision-related quality of life (VrQoL) and quality of life (QoL) were measured in 712 patients with retinal exudative disease receiving anti-VEGF treatment at baseline, 6 and 12 months. VrQoL was measured using an item-response theory based 47-question item bank (EyeQ), whereas QoL was measured using the EuroQol Five Dimensions (EQ-5D) questionnaire. The EQ-5D score was dichotomized into a perfect score of 1 and a suboptimal score of <1. Demographic and clinical patient characteristics were considered as possible predictors of (Vr)QoL. Prediction models for (Vr)QoL were created with linear mixed models and generalised estimating equations, using a forward selection procedure.
A worse VrQoL was predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, longer length of anti-VEGF treatment at baseline and the presence of non-ocular and ocular comorbidities. Suboptimal EQ-5D scores were predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, the presence of non-ocular comorbidities and a lower educational background.
Along with visual acuity of the better eye, which is the main factor used in clinical decision making, other patient characteristics should also be considered for the risk assessment of (Vr)QoL, such as sex, age, civil status, comorbidities and length of anti-VEGF treatment.
确定哪些人口统计学和临床特征可预测接受玻璃体内抗血管内皮生长因子（VEGF）治疗的黄斑水肿患者的视力相关生活质量（VrQoL）和生活质量（QoL）。
在基线、6 个月和 12 个月时，对 712 例接受抗 VEGF 治疗的视网膜渗出性疾病患者进行视力相关生活质量（VrQoL）和生活质量（QoL）测量。VrQoL 通过基于项目反应理论的 47 个问题项库（EyeQ）进行测量，而 QoL 通过 EuroQol Five Dimensions（EQ-5D）问卷进行测量。EQ-5D 评分分为完美得分为 1 和次优得分为 <1。将人口统计学和临床患者特征视为（Vr）QoL 的可能预测因素。使用线性混合模型和广义估计方程，采用向前选择程序，为（Vr）QoL 创建预测模型。
更好眼的 LogMAR 视力越差、女性、单身、年龄越大、基线时抗 VEGF 治疗时间越长以及存在非眼部和眼部合并症，VrQoL 越差。更好眼的 LogMAR 视力越差、女性、单身、年龄越大、存在非眼部合并症以及教育程度较低，预测 EQ-5D 评分较差。
除了视力以外，这是临床决策的主要因素，还应考虑其他患者特征，如性别、年龄、婚姻状况、合并症和抗 VEGF 治疗时间，以评估（Vr）QoL 的风险。
